Thu Nov 9, 2017 9:15am EST
Decision Resources Group Logo. (PRNewsFoto/Decision Resources Group)
Decision Resources Group Logo. (PRNewsFoto/Decision Resources Group)

BURLINGTON, Mass., Nov. 9, 2017 /PRNewswire/ -- Decision Resources Group forecasts the type 1 diabetes (T1D) G7 market to reach $3.9 billion by 2026, with substantial sales growth forecast across the three sub-populations studied. We anticipate several drug launches to capture share from established players, while evolving treatment practice and further newcomers are forecast to expand the market. Market tailwinds include life-long treatment with high-cost agents, polypharmacy, and a rising global T1D incidence.

Other key findings from the Disease Landscape & Forecast report entitled Type 1 Diabetes:

  • The G7 launch of Fiasp, the launch of several biosimilar insulins, and the approval of the SGLT inhibitor class for the treatment of T1D are set to change the T1D treatment landscape through 2026, with displacement of Lantus, NovoLog, and Humalog by their respective biosimilars, and the partial cannibalization of NovoLog by Novo Nordisk's own ultra rapid-acting Fiasp.
  • SGLT inhibitors will provide patients with another treatment option to manage the disease and will likely be used as an adjunct to insulins. Despite later line use, we project the class to command sizeable market share by 2026.
  • Advancements in insulin pump devices through 2026 are set to drive the use of rapid-acting insulins and negate the need for routine use of long-acting insulins in these patients.
  • Top unmet needs in T1D include the existence of extreme blood glucose troughs and peaks that are inherent to T1D, poor adherence to injected treatment, and the unpredictability of response to insulin treatment seen among some patients.

Comments from Decision Resources Group Analyst Kerri Brown:

  • "Our T1D forecast reflects DRG's analysis and consideration of recent and future events. Through 2026, sales of insulins will continue to dominate the T1D market, while sales potential of SGLT inhibitors will be limited by their adjunctive role, and by the absolute requirement for insulin in T1D. Major drivers of market expansion will be life-long treatment with exogenous insulin injections, increasing polypharmacy with the launch of SGLT inhibitors for T1D, and the rising incidence of type 1 diabetes in the G7."
  • "In T1D adults and children, insulin pump use is markedly higher in the United States than the remainder of the G7 countries. These pumps support the increased use of rapid-acting insulins, and negate the need for long-acting insulins. Advances in fully automated, "artificial pancreas" systems are expected to increase the percentage of adults and children using pumps, and further support the sales potential of rapid-acting insulins."

For more information on purchasing this report, please visit our website.

About Decision Resources Group
DRG, a subsidiary of Piramal Enterprises Ltd., is the premier source for global healthcare data and market intelligence. A trusted partner for over 20 years, DRG helps companies competing in the global healthcare industry make informed business decisions. Organizations committed to the developing and delivering life-changing therapies to patients rely on DRG's in-house team of expert healthcare analysts, data scientists, and consultants for critical guidance. DRG products and services, built on extensive data assets and delivered by experts, empower organizations to succeed in complex healthcare markets.

Media contact:

Decision Resources Group
Stephanie Cooper
212-414-7570
scooper@dresources.com

View original content with multimedia:http://www.prnewswire.com/news-releases/drg-publishes-new-type-1-diabetes-content-forecasted-displacement-of-branded-insulins-with-biosimilars-increase-in-treatment-options-with-fiasp-and-sglt-inhibitor-adjuncts-to-insulin-300551905.html

SOURCE Decision Resources Group

To view the original version on PRNewsWire, visit: https://www.prnewswire.com/news-releases/456366813.html

Related Articles